ConeSight Therapeutics

Marie Csete, M.D., Ph.D., CEO

Oct. 13 | 11:30am | BlueRock Therapeutics Ballroom

Pasadena, CA

In-person Presentation
ConeSight Therapeutics is a biotech company dedicated to developing cell-based therapies for blinding diseases, based on discoveries in the lab of Dr. Michael Young at Harvard Medical School. The first product is a cone progenitor cell that regenerates functional cone photoreceptors in the retina in three animal models. Based on a scalable manufacturing plan and compelling preclinical studies, a Phase I/IIa clinical trial in patients with cone-rod dystrophies is anticipated starting in Q3 2023. A Series A funding round is being initiated to take the company through this first clinical trial.

By using this website you agree to accept our Privacy Policy and Terms & Conditions